Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Chang Gung Memorial Hospital
Modality
radiopharmaceutical
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04951817CT.gov 68Ga-PSMA PET/CT for Ra223 Assessment | — | Recruiting | — | — | — |
NCT03977610CT.gov The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ga-68 psma ligand (this asset) | Chang Gung Memorial Hospital | N/A | D · 30 |
| Prednisone | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BB |
| Enzalutamide | AstraZeneca | P4 | BB |
| Leuporelin | Mayo Clinic | P4 | BB |
| Prednisolone | BioNTech SE | P4 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for ga-68 psma ligand
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ga-68 psma ligand in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ga-68-psma-ligand-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →